Eydenzelt® a biosimilar referencing Eylea®, receives a Notice of Compliance from Health Canada (aflibercept 2mg) The approval is based on the totality of evidence, including analytical, nonclinical, and clinical data from global Phase III studies demonstrating Eydenzelt is similar in efficacy and safety for all approved indications Celltrion expands its biosimilars portfolio into ophthalmology reinforcing […]